Founder, Multidisciplinary Association for Psychedelic Studies (MAPS)
Appears in 1 story
Continuing advocacy after FDA's 2024 MDMA rejection
For 55 years, the federal government classified psilocybin, MDMA, LSD, and ibogaine as Schedule I substances. On April 18, 2026, President Trump signed an executive order 'Accelerating Medical Treatments for Serious Mental Illness' directing the FDA to expedite clinical trials of those substances for PTSD in veterans.
Updated May 31
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
